Bremelanotide 1.75 mg dose significantly improved female sexual dysfunction in Phase 2b trial
Background
Subjective endpoints in clinical trials, like those for female sexual dysfunction (FSD), require careful analysis to determine if observed changes are clinically meaningful. Standard statistical significance doesn't always translate to a noticeable improvement for the patient. For conditions like hypoactive sexual desire disorder (HSDD) and female sexual arousal disorder (FSAD), which rely on patient-reported outcomes (PROs), defining a 'responder' is critical. Researchers use minimal clinically important difference (MCID) thresholds to identify what constitutes a real-world benefit. This study aimed to establish these MCID values for various FSD questionnaires and then apply them to analyze the efficacy of bremelanotide, a melanocortin receptor agonist, in a large clinical trial population.
Study Design
This was a responder analysis of data from a large, controlled, phase 2b, dose-finding study. The population consisted of premenopausal women with clinical diagnoses of HSDD, FSAD, or mixed HSDD/FSAD. The study analyzed the change from baseline to the end of the study for 7 distinct patient-reported outcome endpoints. Researchers used four analytical methods to define a clinically meaningful response: expert-based historical anchors, self-reported global benefit, receiver operating characteristic (ROC) curves, and cumulative distribution function analyses. The primary intervention group analyzed was the bremelanotide 1.75 mg subcutaneous dose, compared against a placebo control group within the overall modified intention-to-treat population.
Results
The responder analyses successfully established minimal clinically important differences (MCIDs) for key patient-reported outcomes, including the Female Sexual Function Index-desire domain and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) total score. The MCIDs derived from the ROC curve analyses closely matched the values previously estimated by clinical experts, validating the endpoints. The key efficacy finding was that the bremelanotide 1.75 mg dose demonstrated a statistically significant treatment effect compared to placebo.
For all 7 endpoints evaluated, responder rates in the overall modified intention-to-treat population receiving the 1.75 mg dose were significantly higher than in the placebo group, with P ≤ .03 for every single endpoint.
Bremelanotide was also reported to be safe and well-tolerated in this phase 2b trial. The study confirmed significant improvements in efficacy vs placebo across multiple validated measures of sexual function and distress.
Key Findings
- The 1.75 mg subcutaneous dose of bremelanotide achieved statistically significant responder rates compared with placebo for all 7 endpoints.
- The P-value for the difference between the 1.75 mg dose and placebo was ≤ .03 for every endpoint measured.
- Minimal clinically important differences (MCIDs) determined via ROC curves matched those from clinical expert estimates.
- The responder definitions established in this Phase 2b study were used in the subsequent Phase 3 RECONNECT registration studies.
- Bremelanotide was found to be safe and well-tolerated in the phase 2b trial.
Why It Matters
This study provides robust validation for the 1.75 mg dose of bremelanotide as an effective treatment for premenopausal women with HSDD. The multiple responder analyses offer a sophisticated framework for interpreting patient-reported outcomes, ensuring that the measured benefits are not just statistically significant but also genuinely meaningful to patients. These specific responder definitions and the confirmed efficacy of the 1.75 mg dose were critical for advancing the drug to Phase 3 registration studies (the RECONNECT trials). For clinicians and patients, this solidifies the 1.75 mg dose as the evidence-backed standard for subsequent clinical use, providing confidence that this dose elicits a tangible, clinically important improvement in sexual desire and related distress. The findings directly shaped the final approved dosing protocol for bremelanotide.
TitrateLab articles covering PT-141
Written by TitrateLab, separately from the study summarized above.
